Eli Lilly and Company announced that all three of the nation’s largest pharmacy benefit managers will now cover the company’s full obesity medicine portfolio, including Foundayo and Zepbound, marking a major expansion in insurance access for FDA‑approved obesity treatments. Lilly said this change will allow millions of Americans to obtain its obesity medicines through their existing health plans.
“For too long, effective obesity treatment has been out of reach for the people who need it,” said Ilya Yuffa, executive vice president and president of Lilly USA and global customer capabilities. He added that because not all medicines work the same way for every patient, broader coverage will give patients and their physicians more real‑world choices.
Under the new arrangements, CVS Caremark Commercial Template coverage for Foundayo will begin on June 1. Current Zepbound patients will see their coverage continue without interruption, and access to Zepbound will expand across template plans by October 1. For eligible patients with commercial insurance, both medicines can be obtained for as little as $25 per month.* Beginning July 1, some Medicare Part D beneficiaries may also qualify to pay $50 per month for their obesity medicines through the Medicare GLP‑1 Bridge program.**
Lilly noted that Foundayo is the only once‑daily GLP‑1 pill for weight management that can be taken at any time of day without restrictions on food or water.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!